Abstract
ABSTRACT
The naphthylamine derivative sertraline is a potent and selective inhibitor of serotonin reuptake into presynaptic terminals. Sertraline has a linear pharmacokinetic profile and a half‐life of about 26 h. Its major metabolite, desmethylsertraline does not appear to inhibit serotonin reuptake. Sertraline mildly inhibits the CYP2D6 isoform of the cytochrome P450 system but has little effect on CYP1A2, CYP3A3/4, CYP2C9, or CYP2C19. It is, however, highly protein bound and may alter blood levels of other highly protein bound agents. Sertraline is a widely used serotonin reuptake inhibitor that has been shown to have both antidepressant and antianxiety effects. Many clinical trials have demonstrated its efficacy in depression compared with both placebo and other antidepressant drugs. Its efficacy has also been demonstrated in randomized, controlled trials of patients with obsessive‐compulsive disorder, panic disorder, social phobia, and premenstrual dysphoric disorder. In short‐term, open‐label studies it has appeared efficacious and tolerable in children and adolescents and in the elderly, and data are positive for its use in pregnant or lactating women. Typical side effects include gastrointestinal and central nervous system effects as well as treatment‐emergent sexual dysfunction; withdrawal reactions may be associated with abrupt discontinuation of the agent. The safety profile of sertraline in overdose is very favorable. Sertraline's efficacy for both mood and anxiety disorders, relatively weak effect on the cytochrome P450 system, and tolerability profile and safety in overdose are factors that contribute to make it a first‐line agent for treatment in both primary and tertiary care settings.
SUMMARY
Sertraline is a potent and specific serotonin uptake inhibitor with efficacy in mood and anxiety disorders. Its therapeutic value in major depression, dysthymia, OCD, social phobia, panic disorder, and PMDD has been established. In addition, recent data support its relative safety for use in pregnant and breast‐feeding women. It has relatively weak effects on the cytochrome P450 system, a tolerability profile that is positive compared with antidepressants of other classes, and it is relatively safe in overdose. These findings contribute to sertraline being the first‐line agent for the treatment of several psychiatric disorders.
Keywords: Antidepressants, Anxiety disorders, 5‐HT, 5‐HT‐reuptake, Mood disorders‐Sertraline, SSRIs
Full Text
The Full Text of this article is available as a PDF (199.1 KB).
References
- 1. Aguglia E, Casacchia M, Cassano GB, et al. Double‐blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993;8:197–202. [DOI] [PubMed] [Google Scholar]
- 2. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when co‐administered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284–291. [DOI] [PubMed] [Google Scholar]
- 3. Alderman J, Wolkow R, Chung M, Johnston HF. Sertraline treatment of children and adolescents with obsessive‐compulsive disorder or depression: Pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry 1998;37:386–394. [DOI] [PubMed] [Google Scholar]
- 4. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multipledose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999;19:155–63. [DOI] [PubMed] [Google Scholar]
- 5. Altshuler LL, Burt VK, McMullen M, Hendrick V. Breast‐feeding and sertraline: A 24‐hour analysis. J Clin Psychiatry 1995;56:243–245. [PubMed] [Google Scholar]
- 6. Amsterdam JD. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol 1998;12:S99–S111. [DOI] [PubMed] [Google Scholar]
- 7. Apseloff G, Wilner KD, Gerber N, Tremaine LM. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997;32 (Suppl 1): 37–42. [DOI] [PubMed] [Google Scholar]
- 8. Apseloff G, Wilner KD, von Deutsch DA, et al. Sertraline does not alter steady‐state concentrations or renal clearance of lithium in healthy volunteers. J Clin Pharmacol 1992;32:643–646. [DOI] [PubMed] [Google Scholar]
- 9. Arranz FJ, Ros S. Effects of comorbidity and polypharmacy on the clinical usefulness of sertraline in elderly depressed patients: An open multicentre study. J Affect Disord 1997;46:285–291. [DOI] [PubMed] [Google Scholar]
- 10. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248–251. [DOI] [PubMed] [Google Scholar]
- 11. Banerjee SP, Kung SL, Riggi SJ, Chanda SK. Development of β‐adrenergic receptor sensitivity by antidepressants. Nature 1977;268:455–456. [DOI] [PubMed] [Google Scholar]
- 12. Barbenel DM, Yusufi B, O'Shea D, Bench CJ. Mania in a patient receiving testosterone replacement post‐orchidectomy taking St. John's wort and sertraline. J Psychopharmacol 2000;14:84–86. [DOI] [PubMed] [Google Scholar]
- 13. Bell B, Browne G, Steiner M, et al. The prevalence, co‐morbidity and costs of dysthymia in primary care: Under recognition of the mix of problems. World Psychiatric Association Thematic Conference, Jerusalem, Israel. Program Abstract p. 23, November 1997.
- 14. Bell C, Wilson S, Nutt DJ. Pindolol augmentation of sertraline in resistant depression and its effect on sleep. J Psychopharmacol 1998;12:105–107. [DOI] [PubMed] [Google Scholar]
- 15. Bennie EH, Mullin JM, Martindale JJ. A double‐blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995;56:229–237. [PubMed] [Google Scholar]
- 16. Berti CA, Doogan DP. Sudden chest pain with sertraline. Lancet 1994;343:1510–1511. [DOI] [PubMed] [Google Scholar]
- 17. Beshay H, Pumariega AJ. Sertraline treatment of mood disorder associated with prednisone: A case report. J Child Adolesc Psychopharmacol 1998;8:187–193. [DOI] [PubMed] [Google Scholar]
- 18. Biri H, Isen K, Sinik Z et al. Sertraline in the treatment of premature ejaculation: A double‐blind placebo controlled study. Int Urol Nephrol 1998;30:611–615. [DOI] [PubMed] [Google Scholar]
- 19. Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series. Pediatrics 1999;104:e11. [DOI] [PubMed] [Google Scholar]
- 20. Bisserbe J‐C, Lane RM, Flament M, et al. A double‐blind comparison of sertraline and clomipramine in outpatients with obsessive‐compulsive disorder. Eur Psychiatry 1997;12:82–97. [DOI] [PubMed] [Google Scholar]
- 21. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217–222. [DOI] [PubMed] [Google Scholar]
- 22. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995;45:219–223. [DOI] [PubMed] [Google Scholar]
- 23. Bolden‐Watson C, Richelson E. Blockade by newly‐developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023–1029. [DOI] [PubMed] [Google Scholar]
- 24. Bonate PL, Kroboth PD, Smith RB, et al. Clonazepam and sertraline: Absence of drug interaction in a multiple‐dose study. J Clin Psychopharmacol 2000;20:19–27. [DOI] [PubMed] [Google Scholar]
- 25. Bondareff W, Alpert M, Friedhoff AJ, et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000;157:729–736. [DOI] [PubMed] [Google Scholar]
- 26. Bradford JM, Gratzer TG. A treatment for impulse control disorders and paraphilia: A case report. Can J Psychiatry 1995;40:4–5. [DOI] [PubMed] [Google Scholar]
- 27. Bradley ME, Foote EF, Lee EN, Merkle L. Sertraline‐associated syndrome of inappropriate antidiuretic hormone: Case report and reviews of the literature. Pharmacotherapy 1996;16:680–683. [PubMed] [Google Scholar]
- 28. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder. JAMA 2000;283:1837–1844. [DOI] [PubMed] [Google Scholar]
- 29. Brown CS, Parker N, Ling F, Wan J. Sertraline in contraceptive users with premenstrual dysphoric disorder. Obstet Gynecol 2000;95:S29. [Google Scholar]
- 30. Buchsbaum MS, Wu J, Siegel BV, et al. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 1997;41:15–22. [DOI] [PubMed] [Google Scholar]
- 31. Buck OD. Sertraline for the reduction of violent behavior. Am J Psychiatry 1995;152:953. [DOI] [PubMed] [Google Scholar]
- 32. Burke WJ, Folks DG, Roccaforte WH, et al. Serotonin reuptake inhibitors for the treatment of coexisting depression and psychosis in dementia of the Alzheimer type. Am J Geriatr Psychiatry 1994;2:352–354. [DOI] [PubMed] [Google Scholar]
- 33. Burns A, Russell E, Stratton‐Powell H, et al. Sertraline in stroke‐associated lability of mood. Int J Geriatr Psychiatry 1999;14:681–685. [PubMed] [Google Scholar]
- 34. Byerly MJ, Goodman WK, Christenson R. High doses of sertraline for treatment‐resistant obsessive compulsive disorder. Am J Psychiatry 1996;153:1232–1233. [DOI] [PubMed] [Google Scholar]
- 35. Cantrell R, Gillespie W, Altschuler L. Fluoxetine and sertraline dosages in major depression. Depress Anxiety 1999;9:78–82. [PubMed] [Google Scholar]
- 36. Caracci G. Unsuccessful suicide attempt by sertraline overdose. Am J Psychiatry 1994;151:147. [DOI] [PubMed] [Google Scholar]
- 37. Catalano G, Kanfer SN, Catalano MC, Alberts VA. The role of sertraline in a patient with recurrent hyponatremia. Gen Hosp Psychiatry 1996;18:278–283. [DOI] [PubMed] [Google Scholar]
- 38. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820–822. [DOI] [PubMed] [Google Scholar]
- 39. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. NEngl J Med 1996;335:1010–1015. [DOI] [PubMed] [Google Scholar]
- 40. Chen J, Rasenick MM. Chronic antidepressant treatment facilitates G‐protein activiation of adenylyl cyclase without altering G protein content. J Pharmacol Exp Ther 1995;275:509–517. [PubMed] [Google Scholar]
- 41. Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: Two case reports. J Clin Psychopharmacol 1997;17:68–69. [DOI] [PubMed] [Google Scholar]
- 42. Clary CM, Harrison WM. Elevated serum thyrotropin in thyroxine‐treated patients with hypothyroidism given sertraline (letter to the editor). NEngl J Med 1997;337:1010–1011. [DOI] [PubMed] [Google Scholar]
- 43. Cohn CK, Shrivastava R, Mendels J, et al. Double‐blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990;51 (Suppl B): 28–33. [PubMed] [Google Scholar]
- 44. Constantino JN, Liberman M, Kincaid M. Effects of serotonin reuptake inhibitors on aggressive behavior in psychiatrically hospitalized adolescents: Results of an open trial. J Child Adolesc Psychopharmacol 1997;7:31–44. [DOI] [PubMed] [Google Scholar]
- 45. Coplan JD, Andrews MW, Rosenblum LA, et al. Persistent elevations of cerebrospinal fluid concentrations of corticotropin‐releasing factor in adult non‐human primates exposed to early‐life stressors: Implications for the pathophy siology of mood and anxiety disorders. Proc Natl Acad Sci 1996;93:1619–1623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356–362. [DOI] [PubMed] [Google Scholar]
- 47. Czepowicz VD, Johnson MR, Lydiard RB, et al. Sertraline in social phobia. J Clin Psychopharmacol 1995;15:372–373. [DOI] [PubMed] [Google Scholar]
- 48. de Jonghe F. Sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1997;54:973. [DOI] [PubMed] [Google Scholar]
- 49. Demolis JL, Angebaud P, Grange JD, et al. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol 1996;42:394–397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. DeVane CL, Sallee FR. Serotonin selective re‐uptake inhibitors in child and adolescent psychopharmacology: Areview of published experiences. J Clin Psychiatry 1996;57:55–66. [PubMed] [Google Scholar]
- 51. Dike GL. Triphasic waves in serotonin syndrome. J Neurol Neurosurg Psychiatry 1997;62:200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Dodt JE, Byerly MJ, Cuadros C, Christensen RC. Treatment of risperidone‐induced obsessive‐compulsive symptoms with sertraline. Am J Psychiatry 1997;154:582. [DOI] [PubMed] [Google Scholar]
- 53. Doogan DP. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol 1991;6 (Suppl 2): 47–56. [DOI] [PubMed] [Google Scholar]
- 54. Doogan DP, Caillard V. Sertraline: Anew antidepressant. J Clin Psychiatry 1988;49 (Suppl): 46–51. [PubMed] [Google Scholar]
- 55. Doogan DP, Langdon CJ. A double‐blind, placebo‐controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 1994;9:95–100. [DOI] [PubMed] [Google Scholar]
- 56. Dow B, Kline N. Antidepressant treatment of posttraumatic stress disorder and major depression in veterans. Ann Clin Psychiatry 1997;9:1–5. [DOI] [PubMed] [Google Scholar]
- 57. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597–606. [DOI] [PubMed] [Google Scholar]
- 58. Ekselius L, von Knorring L. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. Int Clin Psychopharmacol 1998;13:205–211. [DOI] [PubMed] [Google Scholar]
- 59. Ekselius L, von Knorring L, Eberhard G. A double‐blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12:323–331. [DOI] [PubMed] [Google Scholar]
- 60. Engel CC Jr, Walker EA, Engel AL, et al. A randomized, double‐blind crossover trial of sertraline in women with chronic pelvic pain. J Psychosom Res 1998;44:203–207. [DOI] [PubMed] [Google Scholar]
- 61. Epperson CN, Anderson GM, McDougle CJ. Sertraline and breast‐feeding. N Engl J Med 1997;336:1189–1190. [DOI] [PubMed] [Google Scholar]
- 62. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol 1999;14 (Suppl 2): S27–S33. [PubMed] [Google Scholar]
- 63. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: A double‐blind fixed‐dose comparison with placebo. Biol Psychiatry 1995;38:592–602. [DOI] [PubMed] [Google Scholar]
- 64. Fava M, Nierenberg AA, Quitkin FM, et al. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull 1997;33:101–103. [PubMed] [Google Scholar]
- 65. Feiger A, Kiev A, Shrivastava RK. Nefazodone vs. sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57 (Suppl 2): 53–62. [PubMed] [Google Scholar]
- 66. Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms. Gen Hosp Psychiatry 1997;19:89–97. [DOI] [PubMed] [Google Scholar]
- 67. Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive‐compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 1998;8:61–67. [DOI] [PubMed] [Google Scholar]
- 68. Findling RL. Open‐label treatment of comorbid depression and attentional disorders with co‐administration of serotonin reuptake inhibitors and psycho stimulants in children, adolescents, and adults: A case series. J Child Adolesc Psychopharmacol 1996;6:165–175. [DOI] [PubMed] [Google Scholar]
- 69. Finkel SI, Richter EM, Clary CM. Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. Int Psychogeriatr 1999;11:85–99. [DOI] [PubMed] [Google Scholar]
- 70. Fisch C, Knoebel SB. Electrocardiographic findings in sertraline depression trials. Drug Invest 1992;4:305–312. [Google Scholar]
- 71. Flament MF, Bisserbe JC. Pharmacologic treatment of obsessive‐compulsive disorder: Comparative studies. J Clin Psychiatry 1997;58:18–22. [PubMed] [Google Scholar]
- 72. Flament MF, Lane RM, Zhu R, Ying Z. Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol 1999;14:259–275. [PubMed] [Google Scholar]
- 73. Franchini L, Gasperini M, Zanardi R, Smeraldi E. Four‐year follow‐up study of sertraline and fluvoxamine in long‐term treatment of unipolar subjects with high recurrence rate. J Affect Disord 2000;58:233–236. [DOI] [PubMed] [Google Scholar]
- 74. Frankenburg FR, Kando JC. Sertraline treatment of attention deficit hyperactivity disorder and Tourette's syndrome. J Clin Psychopharmacol 1994;14:359–360. [DOI] [PubMed] [Google Scholar]
- 75. Freeman EW, Rickels K, Sondheimer SJ, Wittmack FM. Sertraline versus desipramine in the treatment of premenstrual syndrome: An open‐label trial. J Clin Psychiatry 1996;57:7–11. [PubMed] [Google Scholar]
- 76. Freeman EW, Rickels K, Arredondo F, et al. Full‐ or half‐cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999;19:3–8. [DOI] [PubMed] [Google Scholar]
- 77. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder. A randomized controlled trial. Arch Gen Psychiatry 1999;56:932–939. [DOI] [PubMed] [Google Scholar]
- 78. Gardner MJ, Baris BA, Wilner KD, Preskorn SH. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 1997;32 (Suppl 1): 43–49. [DOI] [PubMed] [Google Scholar]
- 79. Ghaziuddin M. Mania induced by sertraline in a prepubertal child. Am J Psychiatry 1994;151:944. [DOI] [PubMed] [Google Scholar]
- 80. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders — III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12 (Suppl B): S55–S87. [DOI] [PubMed] [Google Scholar]
- 81. Goldstein L, Barker M, Segall F, et al. Seizure and transient SIADH associated with sertraline. Am J Psychiatry 1996;153:732. [DOI] [PubMed] [Google Scholar]
- 82. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology. J Psychopharmacol 1998;12 (Suppl B): S5–20. [DOI] [PubMed] [Google Scholar]
- 83. Goodnick PJ, Kumar A, Henry JH, et al. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997;33:261–264. [PubMed] [Google Scholar]
- 84. Gorman JM. The use of newer antidepressants for panic disorder. J Clin Psychiatry 1997;58 (Suppl 14): 54–58. [PubMed] [Google Scholar]
- 85. Graber MA, Hoehns TB, Perry PJ. Sertraline‐phenelzine drug‐interaction: A serotonin syndrome reaction. Ann Pharmacother 1994;28:732–735. [DOI] [PubMed] [Google Scholar]
- 86. Greist J, Chouinard G, DuBoff E, et al. Double‐blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive‐compulsive disorder. Arch Gen Psychiatry 1995;52:289–295. [DOI] [PubMed] [Google Scholar]
- 87. Greist JH, Jefferson JW, Kobak KA, et al. A 1 year double‐blind placebo‐controlled fixed dose study sertraline in the treatment of obsessive‐compulsive disorder. Int Clin Psychopharmacol 1995;10:57–65. [DOI] [PubMed] [Google Scholar]
- 88. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 1997;58 (Suppl 7): 17–22. [PubMed] [Google Scholar]
- 89. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997;58:399–402. [DOI] [PubMed] [Google Scholar]
- 90. Hamilton SP, Nunes EV, Janal M, Weber L. The effect of sertraline on methadone plasma levels in methadone‐maintenance patients. Am J Addict 2000;9:63–69. [DOI] [PubMed] [Google Scholar]
- 91. Hassan PC, Sproule BA, Naranjo CA, Herrmann N. Dose‐response evaluation of the interaction between sertraline and alprazolam in vivo. J Clin Psychopharmacol 2000;20:150–158. [DOI] [PubMed] [Google Scholar]
- 92. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997;12:756–759. [DOI] [PubMed] [Google Scholar]
- 93. Hemeryck A, DeVriendt C, Belpaire FM. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)‐warfarin using human liver microsomes. Eur J Clin Pharmacol 1999;54:947–951. [DOI] [PubMed] [Google Scholar]
- 94. Henney JE. From the Food and Drug Administration. JAMA 2000;283:596. [PubMed] [Google Scholar]
- 95. Heym J, Koe BK. Pharmacology of sertraline: A review. J Clin Psychiatry 1988;49 (Suppl): 40–45. [PubMed] [Google Scholar]
- 96. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11–28. [DOI] [PubMed] [Google Scholar]
- 97. Hindmarch I, Bhatti JZ. Psychopharmacological effects of sertraline in normal, healthy volunteers. Eur J Clin Pharmacol 1988;35:221–223. [DOI] [PubMed] [Google Scholar]
- 98. Hindmarch I, Shillingford J, Shillingford C. The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 1990;51 (Suppl B): 34–36. [PubMed] [Google Scholar]
- 99. Hoehn‐Saric R, Ninan P, Black DW, et al. Multicenter double‐blind comparison of sertraline and desipramine for concurrent obsessive‐compulsive and major depressive disorders. Arch Gen Psychiatry 2000;57:76–82. [DOI] [PubMed] [Google Scholar]
- 100. Hyttel J. Comparative pharmacological studies of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry 1993;47 (Suppl 30): 5–20. [Google Scholar]
- 101. Iruela LM. Sudden chest pain with sertraline. Lancet 1994;343:1106. [DOI] [PubMed] [Google Scholar]
- 102. Jackson C, Carson W, Markowitz J, Mintzer J. SIADH associated with fluoxetine and sertraline therapy. Am J Psychiatry 1995;152:809–810. [PubMed] [Google Scholar]
- 103. Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double‐blind, placebo‐controlled, crossover study. Arch Fam Med 1999;8:328–332. [DOI] [PubMed] [Google Scholar]
- 104. Kalivas J, Kalivas L, Gilman D, Hayden CT. Sertraline in the treatment of neurotic excoriations and related disorders. Arch Dermatol 1996;132:589–590. [DOI] [PubMed] [Google Scholar]
- 105. Kaminski CA, Robbins MS, Weibley RE. Sertraline intoxication in a child. Ann Emerg Med 1994;23:1371–1374. [DOI] [PubMed] [Google Scholar]
- 106. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: A double‐blind, placebo‐controlled crossover study. Am J Psychiatry 1995;152:1368–1371. [DOI] [PubMed] [Google Scholar]
- 107. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998;7:163–165. [DOI] [PubMed] [Google Scholar]
- 108. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double‐blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997;58:532–537. [DOI] [PubMed] [Google Scholar]
- 109. Kellar KJ, Cascio CS, Butler JA, Kurtzke RN. Differential effects of electroconvulsive shock and antide‐pressant drugs on serotonin‐2 receptors in rat brain. Eur J Pharmacol 1981;69:515–518. [DOI] [PubMed] [Google Scholar]
- 110. Keller MB, Gelenberg AJ, Hirschfeld RM, et al. The treatment of chronic depression, part 2: A doubleblind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998;59:598–607. [DOI] [PubMed] [Google Scholar]
- 111. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial. JAMA 1998;280:1665–1672. [DOI] [PubMed] [Google Scholar]
- 112. Kent JM, Coplan JD, Gorman JM. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 1998;44:812–824. [DOI] [PubMed] [Google Scholar]
- 113. Kent LS, Laidlaw JD. Suspected congenital sertraline dependence. Br J Psychiatry 1995;167:412–413. [DOI] [PubMed] [Google Scholar]
- 114. Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: A double‐blind, placebo‐controlled study. J Urol 1998;159:425–427. [DOI] [PubMed] [Google Scholar]
- 115. Kirli S, Caliskan M. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res 1998;33:103–111. [DOI] [PubMed] [Google Scholar]
- 116. Kline NA, Dow BM, Brown SA, et al. Sertraline efficacy in depressed combat veterans with post‐traumatic stress disorder. Am J Psychiatry 1994;151:621. [DOI] [PubMed] [Google Scholar]
- 117. Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline N‐demethylation is catalyzed by multiple isoforms of human cytochrome P‐450 in vitro. DrugMetab Dispos 1999;27:763–766. [PubMed] [Google Scholar]
- 118. Kocsis JH, Zisook S, Davidson J, et al. Double‐blind comparison of sertraline, imipramine and placebo in the treatment of dysthymia: Psychosocial outcomes. Am J Psychiatry 1997;154:390–395. [DOI] [PubMed] [Google Scholar]
- 119. Koe BK. Preclinical pharmacology of sertraline: A potent and specific inhibitor of serotonin reuptake. J Clin Psychiatry 1990;51 (Suppl B): 13–17. [PubMed] [Google Scholar]
- 120. Koe BK, Koch SW, Lebel LA, et al. Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of β‐adrenoceptor system of rat brain. Eur J Pharmacol 1987;141:187–194. [DOI] [PubMed] [Google Scholar]
- 121. Koe BK, Weissman A, Welch WM, Browne RG. Sertraline, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 1983;226:686–700. [PubMed] [Google Scholar]
- 122. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. NEngl J Med 1998;338:1128–1137. [DOI] [PubMed] [Google Scholar]
- 123. Kristensen JH, Ilett KF, Dusci LJ, et al. Distribution and excretion of sertraline and N‐desmethylsertraline in human milk. Br J Clin Pharmacol 1998;45:453–457. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124. Kronig MH, Apter J, Asnis G, et al. Placebo‐controlled, multicenter study of sertraline treatment for obsessive‐compulsive disorder. J Clin Psychopharmacol 1999;19:172–176. [DOI] [PubMed] [Google Scholar]
- 125. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: Aprospective controlled multicenter study. JAMA 1998;279:609–610. [DOI] [PubMed] [Google Scholar]
- 126. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997;62:145–156. [DOI] [PubMed] [Google Scholar]
- 127. Labbate LA, Grimes JB, Arana GW. Serotonin reuptake antidepressant effects on sexual function in Patients with anxiety disorders. Biol Psychiatry 1998;43:904–907. [DOI] [PubMed] [Google Scholar]
- 128. Lane RM. A critical review of selective serotonin reuptake inhibitor‐related sexual dysfunction: Incidence, possible aetiology and implications for management. J Psychopharmacol 1997;11:72–82. [DOI] [PubMed] [Google Scholar]
- 129. Larson M, Folstein S. Selective serotonin reuptake inhibitor‐induced mydriasis. J Am Acad Child Adolesc Psychiatry 2000;39:138–139. [DOI] [PubMed] [Google Scholar]
- 130. Latimer PR, Ravindran AV, Bernatchez J‐P. A six month comparison of toleration and efficacy of sertraline and fluoxetine treatment of major depression. Eur Neuropsychopharmacol 1996;6(Suppl 3): 124. [Google Scholar]
- 131. Lee MS, Kim YK, Lee SK, Suh KY. A double‐blind study of adjunctive sertraline in haloperidol‐stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 1998;18:399–403. [DOI] [PubMed] [Google Scholar]
- 132. Lejoyeux M, Ades J. Antidepressant discontinuation: A review of the literature. J Clin Psychiatry 1997;58 (Suppl 7): 11–15. [PubMed] [Google Scholar]
- 133. Lenk M, Alehan D, Ozme S, et al. The role of serotonin re‐uptake inhibitors in preventing recurrent unexplained childhood syncope — a preliminary report. Eur JPediatr 1997;156:747–750. [DOI] [PubMed] [Google Scholar]
- 134. Leonard HL, March J, Rickler KC, Allan AJ. Pharmacology of the selective re‐uptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997;36:725–736. [DOI] [PubMed] [Google Scholar]
- 135. Lepine JP, Goger J, Blashko C, et al. A double‐blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. Int Clin Psychopharmacol 2000;15:263–271. [DOI] [PubMed] [Google Scholar]
- 136. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: A review of spontaneous reports. CMAJ 1996;155:519–527. [PMC free article] [PubMed] [Google Scholar]
- 137. Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder: A multisite double‐blind, placebo‐controlled fixed dose investigation. Br J Psychiatry 1998;173:54–60. [DOI] [PubMed] [Google Scholar]
- 138. Louie AK, Lannon RA, Ajari LJ. Withdrawal reaction after sertraline discontinuation. Am J Psychiatry 1994;151:450–451. [DOI] [PubMed] [Google Scholar]
- 139. Lydiard RB, Stahl SM, Hertzman M, Harrison WM. A double‐blind, placebo‐controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997;58:484–491. [DOI] [PubMed] [Google Scholar]
- 140. Magai C, Kennedy G, Cohen CI, Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late‐stage Alzheimer's disease. Am J Geriatr Psychiatry 2000;8:66–74. [DOI] [PubMed] [Google Scholar]
- 141. Magarinos AM, McEwen BS, Flugge G, Fuchs E. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. J Neurosci 1996;16:3534–3540. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 142. Malt UF, Robak OH, Madsbu H‐P, et al. The Norwegian naturalistic treatment of study of depression in general practice (NORDEP) — I: randomised double blind study. BMJ 1999;318:1180–1184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143. Mammen OK, Perel JM, Rudolph G, et al. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997;58:100–103. [DOI] [PubMed] [Google Scholar]
- 144. Mancini C, Van Ameringen M, Oakman JM, Farvolden P. Serotonergic agents in the treatment of social phobia in children and adolescents: A case series. Depress Anxiety 1999;10:33–39. [DOI] [PubMed] [Google Scholar]
- 145. March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive‐compulsive disorder: A multicenter randomized controlled trial. JAMA 1998;280:1752–1756. [DOI] [PubMed] [Google Scholar]
- 146. Markowitz JS, DeVane CL. Rifampin‐induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline. J Clin Psychopharmacol 2000;20:109–110. [DOI] [PubMed] [Google Scholar]
- 147. Martins EA, Pigott TA, Bernstein SE, et al. Sertraline in the treatment of patients with social phobia. Anxiety 19941995;1:291–297. [DOI] [PubMed] [Google Scholar]
- 148. Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline co‐administration. Ann Pharmacother 1997;31:175–177. [DOI] [PubMed] [Google Scholar]
- 149. McCowen KC, Garber JR, Spark R. Elevated serum thyrotropin in thyroxin‐treated patients with hypothyroidism given sertraline (letter to the editor). NEngl J Med 1997;337:1010–1011. [DOI] [PubMed] [Google Scholar]
- 150. McDougle CJ, Brodkin ES, Naylor ST, et al. Sertraline in adults with pervasive developmental disorders: A prospective open‐label investigation. J Clin Psychopharmacol 1998;18:62–66. [DOI] [PubMed] [Google Scholar]
- 151. McIntyre IM, King CV, Staikos V, Gall J, Drummer OH. Afatality involving moclobemide, sertraline, and pimozide. J Forensic Sci 1997;42:951–953. [PubMed] [Google Scholar]
- 152. McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: A single‐blind placebo‐controlled crossover study. J Urol 1998;159:1935–1938. [DOI] [PubMed] [Google Scholar]
- 153. Mehtonen O‐P, Søgaard J, Roponen P, Behnke K. Randomized, double‐blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 2000;61:95–100. [DOI] [PubMed] [Google Scholar]
- 154. Minnery KL, West SA, McConville BJ, Sorter MT. Sertraline‐induced mania in an adolescent [letter]. J Child Adolesc Psychopharmacol 1995;5:151–153. [DOI] [PubMed] [Google Scholar]
- 155. Mishra RT, Jankowksy A, Sulser F. Action of mianserin and zimelidine on norepinephrine receptor coupled adenylate cyclase system in the brain: Sub sensitivity without reduction in beta‐adrenergic receptor binding. Neuropharmacology 1980;19:983–987. [DOI] [PubMed] [Google Scholar]
- 156. Mitsikostas DD, Thomas AM. Comorbidity of headache and depressive disorders. Cephalagia 1999;19:211–217. [DOI] [PubMed] [Google Scholar]
- 157. Moller HJ, Gallinat J, Hegerl U, et al. Double‐blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Pharmacopsychiatry 1998;31:170–177. [DOI] [PubMed] [Google Scholar]
- 158. Montejo‐Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176–194. [DOI] [PubMed] [Google Scholar]
- 159. Montgomery SA, Doogan DP, Burnside R. The influence of different relapse criteria on the assessment of long‐term efficacy of sertraline. Int Clin Psychopharmacol 1991;6 (Suppl 2): 37–46. [DOI] [PubMed] [Google Scholar]
- 160. Munjack DJ, Flowers C, Eagan TV. Sertraline in social phobia. Anxiety 19941995;1:196–98. [DOI] [PubMed] [Google Scholar]
- 161. Murdoch D, McTavish D. Sertraline: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive‐compulsive disorder. Drugs 1992;44:604–624. [DOI] [PubMed] [Google Scholar]
- 162. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996;307:117–119. [DOI] [PubMed] [Google Scholar]
- 163. Newhouse PA. Use of serotonin selective reuptake inhibitors in geriatric depression. J Clin Psychiatry 1996;57 (Suppl 5): 12–22. [PubMed] [Google Scholar]
- 164. Newhouse PA, Ko G, Richter EM. Comparison of sertraline and fluoxetine in depressed geriatric outpatients: Plasma levels and efficacy. Eur Neuropsychopharmacol 1996;6(Suppl 3): 35. [Google Scholar]
- 165. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995;15:7539–7547. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 166. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365–2372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 167. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993;53:84–88. [DOI] [PubMed] [Google Scholar]
- 168. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. NEngl J Med 1997;336:258–262. [DOI] [PubMed] [Google Scholar]
- 169. Nutt D, Lawson C. Panic attacks: A neurochemical overview of models and mechanisms. Br J Psychiatry 1992;160:165–178. [DOI] [PubMed] [Google Scholar]
- 170. Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monamine oxidase inhibitor. Neurology 1960;10:1076–1078. [DOI] [PubMed] [Google Scholar]
- 171. Olie JP, Gunn KP, Katz E. A double‐blind placebo‐controlled multicentre study of sertraline on the acute and continuation treatment of major depression. Eur Psychiatry 1997;12:34–11. [DOI] [PubMed] [Google Scholar]
- 172. Oslin DW, Streim JE, Katz IR, et al. Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients. Am J Geriatr Psychiatry 2000;8:141–149. [PubMed] [Google Scholar]
- 173. Ozdemir V, Naranjo CA, Herrmann N, et al. The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. J Clin Psychopharmacol 1998;18:55–61. [DOI] [PubMed] [Google Scholar]
- 174. Pandey GN, Heinze WJ, Brown BD, Davis JM. Electroconvulsive shock treatment decreases P‐adrenergic receptor sensitivity in rat brain. Nature 1979;280:234–235. [DOI] [PubMed] [Google Scholar]
- 175. Pao M, Tipnis T. Serotonin syndrome after sertraline overdose in a 5‐year‐old girl. Arch Pediatr Adolesc Med 1997;151:1064–1067. [DOI] [PubMed] [Google Scholar]
- 176. Pastuszak A, Schick‐Boschetto B, Zuber C, et al. Pregnancy outcome following first‐trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246–2248. [PubMed] [Google Scholar]
- 177. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101–109. [DOI] [PubMed] [Google Scholar]
- 178. Perry CM, Benfield P. Sertraline. An overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive‐compulsive disorder. CNS Drugs 1997;7:480–500. [Google Scholar]
- 179. Peterson KA, Armstrong S, Moseley J. Pathologic crying responsive to treatment with sertraline. J Clin Psychopharmacol 1996;16:333. [DOI] [PubMed] [Google Scholar]
- 180. . Pfizer Canada Inc. : Zoloft product monograph. December 1996.
- 181. Piggott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive‐compulsive disorder. J Clin Psychiatry 1999;60:101–106. [DOI] [PubMed] [Google Scholar]
- 182. Pihoker C, Owens MJ, Kuhn CM, et al. Maternal separation in neonatal rats elicits activation of the hypo‐thalamic‐pituitary‐adrenocortical axis: A putative role for corticotropin releasing factor. Psychoneuroendocrinology 1993;18:485–493. [DOI] [PubMed] [Google Scholar]
- 183. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984–990. [PubMed] [Google Scholar]
- 184. Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder. A flexible‐dose multicenter trial. Arch Gen Psychiatry 1998;55:1010–1016. [DOI] [PubMed] [Google Scholar]
- 185. Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 1997;33:235–241. [PubMed] [Google Scholar]
- 186. Post RM. Molecular biology of behavior: Targets for therapeutics. Arch Gen Psychiatry 1997;54:607–608. [DOI] [PubMed] [Google Scholar]
- 187. Preskorn SH. Debate resolved: There are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. J Psychopharmacol 1998;12 (Suppl B): S89–97. [DOI] [PubMed] [Google Scholar]
- 188. Preskorn SH, Lane RM. Sertraline 50 mg daily: The optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995;10:129–141. [DOI] [PubMed] [Google Scholar]
- 189. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine co‐administered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90–98. [PubMed] [Google Scholar]
- 190. Preskorn SH, Alderman J, Greenblatt DJ, Horst WD. Sertraline does not inhibit cytochrome (P450) 3A‐mediated drug metabolism in vivo. Psychopharmacol Bull 1997;33:659–665. [PubMed] [Google Scholar]
- 191. Pujol JF, Keane P, McCrae A, et al. Biochemical evidence for serotonergic control of the locus coeruleus In: Garatini S, Pujol JF, Samanin R, Eds. Interactions between putative neurotransmitters in the brain. New York : Raven Press; 1978:401–410. [Google Scholar]
- 192. Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressivenesss in Huntington's disease. J Neuropsychiatry Clin Neurosci 1996;8:338–340. [DOI] [PubMed] [Google Scholar]
- 193. Rapeport WG, Coates PE, Dewland PM, Forster PL. Absence of a sertraline‐mediated effect on digoxin pharmacokinetics and electrocardiographic findings. J Clin Psychiatry 1996;57 (Suppl 1): 16–19. [PubMed] [Google Scholar]
- 194. Rapeport WG, Muirhead DC, Williams SA, et al. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 1996;57 (Suppl 1): 24–28. [PubMed] [Google Scholar]
- 195. Rapeport WG, Williams SA, Muirhead DC, et al. Absence of a sertraline‐mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57 (Suppl 1): 20–23. [PubMed] [Google Scholar]
- 196. Rasmussen S, Hackett E, DuBoff E, et al. A 2‐year study of sertraline in the treatment of obsessive‐compulsive disorder. Int Clin Psychopharmacol 1997;12:309–316. [DOI] [PubMed] [Google Scholar]
- 197. Ravindran AV, Anisman H, Merali Z, et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: Clinical symptoms and functional impairments. Am J Psychiatry 1999;156:1608–1617. [DOI] [PubMed] [Google Scholar]
- 198. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: A double‐blind, placebo‐and amitryptyline‐controlled, multicenter comparison in outpatients with major depression. J Clin Psychiatry 1990;51 (Suppl B): 18–27. [PubMed] [Google Scholar]
- 199. Robert JM, Lydiard RB. Sertraline in the treatment of bulimia nervosa. Am J Psychiatry 1993;150:1753. [DOI] [PubMed] [Google Scholar]
- 200. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N‐demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997;32 (Suppl 1): 22–30. [DOI] [PubMed] [Google Scholar]
- 201. Ronfeld RA, Wilner KD, Baris BA. Sertraline. Chronopharmacokinetics and the effect of co‐administration with food. Clin Pharmacokinet 1997;32 (Suppl 1): 50–55. [DOI] [PubMed] [Google Scholar]
- 202. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998;44:77–87. [DOI] [PubMed] [Google Scholar]
- 203. Rothbaum BO, Ninan PT, Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Trauma Stress 1996;9:865–871. [DOI] [PubMed] [Google Scholar]
- 204. Sánchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999;19:467–489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 205. Sánchez C, Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Psychopharmacology 1997;129:197–205. [DOI] [PubMed] [Google Scholar]
- 206. Sapolsky RM, Uno H, Rebert CS, Finch CE. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 1990;10:2897–2902. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 207. Schwenk MH, Verga MA, Wagner JD. Hemodialyzability of sertraline. Clin Nephrol 1995;44:121–124. [PubMed] [Google Scholar]
- 208. Scott TF, Nussbaum P, McConnell H, Brill P. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res 1995;17:421–422. [PubMed] [Google Scholar]
- 209. Segraves RT, Kavoussi R, Hughes AR, et al. Evaluation of sexual functioning in depressed outpatients: A double‐blind comparison of sustained‐release bupropion and sertraline treatment. J Clin Psychopharmacol 2000;20:122–128. [DOI] [PubMed] [Google Scholar]
- 210. Shapiro PA, Lesperance F, Frasure‐Smith N, et al. An open‐label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT trial). Sertraline anti‐depressant heart attack trial. Am Heart J 1999;137:1100–1106. [DOI] [PubMed] [Google Scholar]
- 211. Shatzberg AF, Haddad P, Kaplan EM, et al. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. J Clin Psychiatry 1997;58 (Suppl 7): 5–10. [PubMed] [Google Scholar]
- 212. Sheehan DV. Current concepts in the treatment of panic disorder. J Clin Psychiatry 1999;60 (Suppl 18): 16–21. [PubMed] [Google Scholar]
- 213. Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease. Am JMed 1997;102:54–59. [DOI] [PubMed] [Google Scholar]
- 214. Sheline YI, Wang PW, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl AcadSci 1996;93:3908–3913. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 215. Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N EnglJ Med 1999;341:1329–1335. [DOI] [PubMed] [Google Scholar]
- 216. Solai LK, Mulsant BH, Pollock BG, et al. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 1997;58:440–443. [DOI] [PubMed] [Google Scholar]
- 217. Sprenger D. Sertraline for nocturnal enuresis. J Am Acad Child Adolesc Psychiatry 1997:36:304–305. [DOI] [PubMed] [Google Scholar]
- 218. Sproule BA, Otton SV, Cheung SW, et al. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997;17:102–106. [DOI] [PubMed] [Google Scholar]
- 219. Sprouse J, Clarke T, Reynolds L, et al. Comparison of the effects of sertraline and its metabolite, desmethylsertraline on blockade of central 5‐HT reuptake in vivo. Neuropsychopharmacology 1996;14:225–231. [DOI] [PubMed] [Google Scholar]
- 220. Steiner M, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. CNS Drugs 2000;13:287–304. [Google Scholar]
- 221. Steiner M, Browne G, Roberts J, et al. Treating dysthymia in primary care: Sertraline vs. IPT (a two‐year followup). Biol Psychiatry 2000;47:91S. [Google Scholar]
- 222. Steiner M, Judge R, Kumar R. Serotonin reuptake inhibitors in the treatment of premenstrual dysphoria: current state of knowledge. Int J Psych Clin Pract 1997;1:241–247. [DOI] [PubMed] [Google Scholar]
- 223. Steingard RJ, Zimnitzky B, DeMaso DR, et al. Sertraline treatment of transition‐associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 1997;7:9–15. [DOI] [PubMed] [Google Scholar]
- 224. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705–713. [DOI] [PubMed] [Google Scholar]
- 225. Stowe ZN, Casarella J, Landry J, Nemeroff CB. Sertraline in the treatment of women with postpartum major depression. Depression 1995;3:49–55. [Google Scholar]
- 226. Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethylsertraline in human breast milk and Nursing infants. Am J Psychiatry 1997;154:1255–1260. [DOI] [PubMed] [Google Scholar]
- 227. Sulser F, Janowsky AJ, Okada F, et al. Regulation of recognition and action function of norepinephrine receptor‐coupled adenylate cyclase system in brain: Implications for the therapy of depression. Neuropharmacology 1983;22:425–431. [DOI] [PubMed] [Google Scholar]
- 228. Sunderji R, Press N, Amin H, Gin K. Unstable angina associated with sertraline. Can J Cardiol 1997;13:849–851. [PubMed] [Google Scholar]
- 229. Taragano F, Lyketsos CG, Paz J, et al. An open‐label trial of sertraline for the treatment of major depression in primary care. Ann Clin Psychiatry 1999;11:67–71. [DOI] [PubMed] [Google Scholar]
- 230. Thase ME, Fava M, Halbreich U, et al. A placebo‐controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996;53:777–784. [DOI] [PubMed] [Google Scholar]
- 231. Thompson C, Lane R, Wiseman R. Safety and efficacy of sertraline in elderly versus young depressed patients in primary care. Neuropsychopharmacology 1994;10:106S. [Google Scholar]
- 232. Tierney E, Joshi PT, Llinas JF. Sertraline for major depression in children and adolescents: Preliminary clinical experience. J Child Adolesc Psychopharmacol 1995;5:13–27. [Google Scholar]
- 233. Tune LE. Depression and Alzheimer's disease. Depress Anxiety 1998;8 (Suppl 1): 91–95. [PubMed] [Google Scholar]
- 234. Van Ameringen M, Mancini C, Oakman J. SSRIs in the treatment of social phobia: The emerging gold standard. CNS Drugs 1999:11:307–315. [Google Scholar]
- 235. Van Ameringen M, Mancini C, Streiner D. Sertraline in social phobia. J Affect Disord 1994;31:141–145. [DOI] [PubMed] [Google Scholar]
- 236. Van Ameringen MA, Bowen RC, Chokka PR, et al. Sertraline treatment of social phobia: A 20‐week, double‐blind, placebo‐controlled study. Presented at the 37th Annual Meeting of the American College of Neuropsychopharmacology, San Juan , Puerto Rico , December 1418, 1998.
- 237. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacoknet 1993;24:203–220. [DOI] [PubMed] [Google Scholar]
- 238. Van Moffaert M, Bartholome F, Cosyns P, et al. A controlled comparison of sertraline and fluoxetine in acute and continuation therapy of major depression. Hum Psychopharmacol 1995;10:393–405. [Google Scholar]
- 239. Varia I, Logue E, Newby K, Krishnan R. Sertraline treatment in non‐cardiac chest pain. A randomized double‐blind trial. New Clinical Drugs Evaluation Unit Annual Meeting, Boca Raton , FL , 1999.Abstract book, poster #192.
- 240. Wadden TA, Bartlett SJ, Foster GD, et al. Sertraline and relapse prevention training following treatment by very‐low‐calorie diet: A controlled clinical trial. Obes Res 1995;3:549–557. [DOI] [PubMed] [Google Scholar]
- 241. Walker JR, Van Ameringen MA, Swinson RP, Lane RM. A 24‐week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. New Research Abstracts. Presented at: Annual Meeting of the American Psychiatric Association; Chicago , IL : May 1318, 2000.
- 242. Warnock JK, Bundren JC, Morris DW. Sertraline in the treatment of depression associated with gonadotropin‐releasing hormone agonist therapy. Biol Psychiatry 1998;43:464–465. [DOI] [PubMed] [Google Scholar]
- 243. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991;6 (Suppl 2): 11–21. [DOI] [PubMed] [Google Scholar]
- 244. Wilner KD, Baris BA, Foulds GH. Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of renal impairment. Eur Neuropsychopharmacol 1996;6(Suppl 3): 41. [Google Scholar]
- 245. Wilson K, Berti C, Whitehead A. The efficacy of sertraline in elderly patients suffering from major depression. Biol Psychiatry 1997;42:242S. [Google Scholar]
- 246. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999;282:1264–1269. [DOI] [PubMed] [Google Scholar]
- 247. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast‐feeding. Am J Psychiatry 1996;153:1132–1137. [DOI] [PubMed] [Google Scholar]
- 248. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: Arandomized controlled trial. JAMA 1997;278:983–988. [PubMed] [Google Scholar]
- 249. Young AH, Currie A, Ashton CH. Antidepressant withdrawal syndrome. Br J Psychiatry 1997;170:288. [DOI] [PubMed] [Google Scholar]
- 250. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double‐blind, placebo‐controlled crossover trial. J Clin Psychiatry 1998;59:76–80. [DOI] [PubMed] [Google Scholar]
- 251. Zanardi R, Franchini L, Gasperini M, et al. Double‐blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996;153:1631–1633. [DOI] [PubMed] [Google Scholar]
- 252. Ziegler MG, Wilner KD. Sertraline does not alter the β‐adrenergic blocking activity of atenolol in healthy male volunteers. J Clin Psychiatry 1996;57 (Suppl 1): 12–15. [PubMed] [Google Scholar]
- 253. Zinner SH. Panic attacks precipitated by sertraline [letter]. Am J Psychiatry 1994;151:147–148. [DOI] [PubMed] [Google Scholar]
- 254. Zussman BD, Davie CC, Fowles SE, et al. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br J Clin Pharmacol 1995;39:550P–551P. [Google Scholar]